News & Views
Latest News & Views
News & Views
First patient dosed in Phase 1 Trial
Iksuda announces first patient dosed in Phase 1 trial of IKS014


Iksuda deepens clinical pipeline
Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 antibody drug conjugate programme from LegoChem Biosciences

Licensing agreement with LegoChem Biosciences
LegoChem Biosciences and Iksuda enter Licensing Agreement for Antibody Drug Conjugate program

LCB and Iksuda Enter into a Multi-Target Research Collaboration
LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression
IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer

Sign up for more news
Thank you